Mantle Cell Lymphoma

A prospective trial showed that treatment with ibrutinib might prompt a decrease in  progression-free survival in patients with relapsed or refractory mantle cell lymphoma, according to long-term follow-up data presented at the 2019 American Society for Hematology Annual Meeting and Exposition.

<br /> Diego Villa, MD, MPH, clinical associate professor, Division of Medical Oncology, The University of British Columbia, discusses a retrospective analysis evaluating bendamustine and rituximab as induction therapy in both transplant eligible and ineligible patients with mantle cell lymphoma.&nbsp;<br /> &nbsp;

In November 2019, the FDA approved a number of treatments, including acalabrutinib for the treatment of chronic lymphocytic leukemia and small lymphocytic leukemia, as well as zanubrutinib for the treatment of mantle cell lymphoma. A biosimilar for pegfilgrastim was also approved under indications.

Andre H. Goy, MD, predicts the future use of novel combinations for treatment of mantle cell lymphoma.

In an interview with <em>Targeted Oncology</em>, Lalit Sehgal, PhD, discussed the rationale for investigating how the tumor microenvironment impacts survival in patients with mantle cell lymphoma through various signaling pathways.&nbsp;

Five-year outcomes data from the S1106 phase II trial in patients with newly diagnosed mantle cell lymphoma found that the RB regimen was equally effective but less toxic than the RH regimen.&nbsp;<br /> &nbsp;

The FDA has granted an accelerated approval to zanubrutinib for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

In an interview with&nbsp;Targeted Oncology, Jia Ruan, MD, PhD, examined the evolving treatment landscape for mantle cell lymphoma. She also discussed modern strategies like precision medicine and ctDNA liquid biopsy that are aiding the evolution.

Simon Rule, MD, PhD, shares his thoughts on the&nbsp;FDA&rsquo;s decision to grant zanubrutinib, a BTK inhibitor, priority review for the treatment of patients with mantle cell lymphoma. Should the drug be approved, it will be available for patients with MCL who have received at least 1 prior line of therapy.

Target resequencing and DNA profiling of purified tumor samples collected from younger patients with mantle cell lymphoma found that mutations of <em>KMT2D</em> and disruption of <em>TP53</em> by deletion or mutation were associated with an increased risk of progression and death, both in univariate and multivariate analysis, from standard treatments, according to a study published recently in <em>Haematologica</em>.<br /> &nbsp;

The phase I/II CIRLL trial has opened an expansion cohort to include patients with mantle cell lymphoma in the study of the monoclonal antibody, cirmtuzumab, plus ibrutinib. The study was previously open to patients with chronic lymphocytic leukemia and small lymphocytic leukemia only.¹

Emerging from the recent 2019 World Conference on Lung Cancer&nbsp;are several notable developments, Robert L. Ferris, MD, PhD, wrote in this issue of&nbsp;<em>Targeted Therapies in Oncology.&nbsp;</em>

Barbara Pro, MD, spoke with a group of physicians during a <em>Targeted Oncology </em>live case-based peer perspectives discussion about the diagnosis, prognosis, and treatment of patients with Hodgkin lymphoma based on the case&nbsp;of a young woman with classic Hodgkin lymphoma.

Michael Wang, MD, discusses the potential role for the next-generation Bruton&#39;s tyrosine kinase inhibitor zanubrutinib compared with first- and second-generation BTK inhibitors for the treatment of patients with mantle cell lymphoma.

In an interview with&nbsp;Targeted Oncology, Ezzat Elhassadi, MD, discussed the results from this analysis and how the presence of a&nbsp;TP53&nbsp;mutation can impact the survival of patients with MCL. He also highlighted the remaining challenges in this space and how these challenges can be overcome.

In an interview with <em>Targeted Oncology</em>, Simon Rule, MD, gave an overview of the standard of care for MCL, which he recently presented at the 2019 SOHO Annual Meeting.

In an interview with&nbsp;Targeted Oncology, Matthew S. Ning, MD, MPH, discussed the role for low-dose radiotherapy as treatment of patients with relapsed/refractory MCL, according to the findings from a recent analysis. He also highlighted how a multidisciplinary approach can impact the treatment of patients with MCL.

Here&#39;s a look back on the FDA happenings for the month of August 2019, including FDA approvals, priority reviews, and breakthrough designations.

In an interview with&nbsp;Targeted Oncology, Sattva S. Neelapu, MD, discussed the evolving role for CAR T-cell therapy in patients with B-cell lymphomas. He also highlighted the toxicities commonly associated with these therapies and how physicians can treat these AEs as they arise.

Peter Martin, MD, discusses the differences between subgroups of mantle cell lymphoma. MCL is a heterogenous disease, and in the World Health Organization classification of lymphoid neoplasms, MCL has a leukemia non-nodal presentation, says Martin.

The FDA has granted a New Drug Application for zanubrutinib a priority review for the treatment of patients with mantle cell lymphoma who have previously received at least 1 prior treatment.

A combination of vorinostat, cladribine, and rituximab demonstrated high, durable rates of complete response in patients with previously untreated mantle cell lymphoma, according to the results of a phase I/II trial of the triplet regimen in patients with non-Hodgkin lymphoma.<br /> &nbsp;

Kieron Dunleavy, MD, discussed current approaches to treating patients with MCL, highlighting peer discussions on the subject and information about the ZUMA-2 trial, in an interview with&nbsp;<em>Targeted Oncology</em>.

Simon Rule, MD, PhD, discusses the current treatment approaches for patients with mantle cell lymphoma in both the United Kingdom and the United States. He says treatment strategies are pretty well established on both sides of the Atlantic Ocean.

In an interview with <em>Targeted Oncology</em>, Peter Martin, MD, assistant professor of medicine, Division of Hematology/Oncology, Weil Cornell Medicine, recounts physician crossfire discussions related to frontline MCL treatment and provides his own expert opinion on the subject.